MMMT
MCID: CRC021
MIFTS: 62

Carcinosarcoma (MMMT)

Categories: Bone diseases, Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Carcinosarcoma

MalaCards integrated aliases for Carcinosarcoma:

Name: Carcinosarcoma 12 54 56 45 15
Malignant Mixed Mullerian Tumor 12 54
Mixed Tumor, Mesodermal 45 17
Mixed Tumor, Mullerian 54 45
Mmmt 12 54
Malignant Mixed Mesodermal Tumor 12
Malignant Mixed Müllerian Tumor 77
Mixed Mesodermal Tumor 12
Mesodermal Mixed Tumor 12
Mullerian Mixed Tumor 12
Mixed Müllerian Tumor 77
Mixed Mullerian Tumor 54
Mixed Tumor Mullerian 56

Classifications:



External Ids:

Disease Ontology 12 DOID:4236
SNOMED-CT 69 63264007 84427001

Summaries for Carcinosarcoma

NIH Rare Diseases : 54 A malignant mixed müllerian tumor (MMMT), also called a carcinosarcoma, is a type of cancer that contains two types of cancer cells - carcinoma and sarcoma cells. These tumors usually develop in tissues of the female genital tract and are associated with a poor outcome. The majority of these tumors arise in the uterus, though they can also occur in the ovaries, fallopian tubes, and cervix. Very rarely, MMMTs can develop in the female peritoneum (lining of the abdominal wall).

MalaCards based summary : Carcinosarcoma, also known as malignant mixed mullerian tumor, is related to cervical carcinosarcoma and uterine carcinosarcoma. An important gene associated with Carcinosarcoma is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Wikipedia : 77 A malignant mixed Müllerian tumor, also known as malignant mixed mesodermal tumor (MMMT) is a cancer... more...

Related Diseases for Carcinosarcoma

Diseases related to Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 498)
# Related Disease Score Top Affiliating Genes
1 cervical carcinosarcoma 33.5 MME PGR TP53
2 uterine carcinosarcoma 32.0 CTNNB1 ERBB2 HRAS KIT MME PGR
3 adenosarcoma 31.6 DES KIT MME PGR TP53
4 adenomyoma 31.2 CTNNB1 KRT7 MME MUC1
5 papillary serous adenocarcinoma 30.3 KRT7 PGR TP53
6 rhabdomyosarcoma 30.3 ACTC1 DES TP53 VIM
7 papilloma 30.3 KRT7 PTEN TP53
8 breast metaplastic carcinoma 30.3 ERBB2 PGR
9 uterine sarcoma 30.2 DES KIT MME
10 liposarcoma 30.2 DES TP53 VIM
11 pleomorphic adenoma 30.1 ACTC1 ERBB2 MUC1 TP53 VIM
12 uterine corpus serous adenocarcinoma 30.1 ERBB2 PIK3CA TP53
13 pulmonary blastoma 30.1 DES KRAS TP53
14 thymoma 30.1 HRAS KIT TP53
15 spindle cell thymoma 30.1 DES MUC1
16 epithelial-myoepithelial carcinoma 29.9 HRAS KRT7 TP53
17 spiradenoma 29.9 ACTC1 KRT7 MUC1 TP53
18 pleomorphic liposarcoma 29.9 DES MUC1 VIM
19 fallopian tube carcinoma 29.9 ERBB2 PGR TP53
20 mucoepidermoid carcinoma 29.9 ERBB2 KRT7 MUC1
21 teratoma 29.9 ACTC1 KIT KRT7 TP53
22 in situ carcinoma 29.9 ERBB2 PGR TP53
23 tubular adenocarcinoma 29.8 ERBB2 MUC1 PGR
24 spindle cell carcinoma 29.8 ACTC1 DES KRT7 MUC1 PGR VIM
25 squamous cell carcinoma 29.8 CTNNB1 ERBB2 HRAS MUC1 PIK3CA PTEN
26 adenofibroma 29.8 ACTC1 MME MUC1 VIM
27 spindle cell sarcoma 29.7 ACTC1 DES KRT7 MUC1 VIM
28 fibrous histiocytoma 29.7 ACTC1 DES VIM
29 dermoid cyst 29.7 KIT KRT7 MUC1 PGR VIM
30 ovarian cancer 1 29.7 ERBB2 KRAS KRT7 PIK3CA TP53
31 merkel cell carcinoma 29.6 KIT KRT7 MUC1 TP53
32 gliosarcoma 29.6 ACTC1 PTEN TP53 VIM
33 leiomyosarcoma 29.6 ACTC1 DES KIT PGR TP53 VIM
34 angiosarcoma 29.5 KIT KRAS MUC1 VIM
35 malignant fibroxanthoma 29.5 ACTC1 DES MUC1 VIM
36 mucinous adenocarcinoma 29.5 KRAS KRT7 MUC1
37 serous cystadenocarcinoma 29.5 ERBB2 HRAS PGR PIK3CA TP53
38 small cell cancer of the lung 29.5 KIT KRT7 PIK3CA PTEN TP53
39 undifferentiated pleomorphic sarcoma 29.4 KIT KRAS PIK3CA
40 chordoma 29.4 DES KRT7 MUC1 PTEN VIM
41 sarcoma 29.4 CTNNB1 HRAS KIT KRAS PIK3CA TP53
42 ovary adenocarcinoma 29.3 ERBB2 HRAS KRAS KRT7 PIK3CA TP53
43 inflammatory myofibroblastic tumor 29.2 ACTC1 DES KIT TP53 VIM
44 papillary adenocarcinoma 29.2 ERBB2 KRT7 MUC1 PGR TP53 VIM
45 cystadenocarcinoma 29.1 ERBB2 HRAS KRT7 MUC1 PGR PIK3CA
46 wilms tumor 1 29.1 CTNNB1 ERBB2 KRT7 PGR TP53
47 cervical cancer 29.1 CTNNB1 ERBB2 HRAS PIK3CA PTEN TP53
48 adenosquamous carcinoma 29.0 KIT KRAS KRT7 MUC1 PIK3CA TP53
49 endometrial stromal sarcoma 28.9 ACTC1 DES KIT MME PGR TP53
50 adenocarcinoma 28.8 CTNNB1 ERBB2 HRAS KIT KRAS MUC1

Graphical network of the top 20 diseases related to Carcinosarcoma:



Diseases related to Carcinosarcoma

Symptoms & Phenotypes for Carcinosarcoma

GenomeRNAi Phenotypes related to Carcinosarcoma according to GeneCards Suite gene sharing:

27 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.3 HRAS KRAS MUC1 PIK3CA
2 Decreased viability GR00106-A-0 10.3 KRAS
3 Decreased viability GR00221-A-1 10.3 HRAS KRAS PIK3CA
4 Decreased viability GR00221-A-2 10.3 HRAS KRAS PIK3CA
5 Decreased viability GR00221-A-3 10.3 HRAS
6 Decreased viability GR00221-A-4 10.3 PIK3CA
7 Decreased viability GR00301-A 10.3 KRAS
8 Decreased viability GR00381-A-1 10.3 KRAS
9 Decreased viability GR00402-S-2 10.3 HRAS KRAS MUC1 PIK3CA
10 Decreased viability in esophageal squamous lineage GR00235-A 10 CTNNB1 DES ERBB2 HRAS KIT KRAS
11 Decreased cell migration GR00055-A-1 9.88 CTNNB1 HRAS KRAS MUC1 PIK3CA VIM
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.85 CTNNB1 ERBB2 HRAS MUC1 PTEN VIM
13 Increased cell death HMECs cells GR00103-A-0 9.55 CTNNB1 PGR PIK3CA PTEN TP53
14 Increased cell migration GR00055-A-3 9.26 CTNNB1 HRAS KRAS PIK3CA
15 Reduced mammosphere formation GR00396-S 9.1 DES HRAS KRAS KRT7 PTEN VIM

MGI Mouse Phenotypes related to Carcinosarcoma:

47 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
2 cardiovascular system MP:0005385 10.38 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
3 cellular MP:0005384 10.38 ACTC1 CTNNB1 DES ERBB2 KIT KRAS
4 behavior/neurological MP:0005386 10.35 CTNNB1 DES ERBB2 HRAS KIT KRAS
5 mortality/aging MP:0010768 10.29 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
6 integument MP:0010771 10.24 CTNNB1 ERBB2 HRAS KIT KRAS MME
7 muscle MP:0005369 10.24 ACTC1 CTNNB1 DES ERBB2 KIT KRAS
8 embryo MP:0005380 10.23 CTNNB1 ERBB2 KIT KRAS PGR PIK3CA
9 endocrine/exocrine gland MP:0005379 10.22 CTNNB1 ERBB2 HRAS KIT KRAS PGR
10 immune system MP:0005387 10.2 CTNNB1 KIT KRAS MME PGR PIK3CA
11 digestive/alimentary MP:0005381 10.13 CTNNB1 ERBB2 HRAS KIT KRAS PTEN
12 neoplasm MP:0002006 10.13 CTNNB1 ERBB2 HRAS KIT KRAS PGR
13 nervous system MP:0003631 10.11 CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
14 craniofacial MP:0005382 10.07 CTNNB1 ERBB2 HRAS KIT KRAS TP53
15 limbs/digits/tail MP:0005371 10.07 CTNNB1 ERBB2 KIT KRAS PGR PTEN
16 normal MP:0002873 10.06 ACTC1 CTNNB1 ERBB2 HRAS KIT KRAS
17 no phenotypic analysis MP:0003012 9.98 CTNNB1 HRAS KIT KRAS PGR PIK3CA
18 reproductive system MP:0005389 9.91 CTNNB1 ERBB2 KIT KRAS PGR PIK3CA
19 renal/urinary system MP:0005367 9.87 CTNNB1 HRAS KIT KRAS KRT7 PTEN
20 pigmentation MP:0001186 9.77 CTNNB1 KIT KRAS PTEN TP53
21 respiratory system MP:0005388 9.76 CTNNB1 ERBB2 HRAS KIT KRAS PTEN
22 skeleton MP:0005390 9.61 CTNNB1 ERBB2 HRAS KIT KRAS PGR
23 vision/eye MP:0005391 9.17 CTNNB1 KIT KRAS PIK3CA PTEN TP53

Drugs & Therapeutics for Carcinosarcoma

Drugs for Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
3
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
4
Ifosfamide Approved Phase 3,Phase 2 3778-73-2 3690
5
Lenograstim Approved, Investigational Phase 3,Phase 1 135968-09-1
6
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
7
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
8
Mesna Approved, Investigational Phase 3,Phase 2 3375-50-6 598
9
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
10
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
11
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
12
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
13
Cyproheptadine Approved Phase 3 129-03-3 2913
14
Histamine Approved, Investigational Phase 3 51-45-6 774
15
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
16 Antineoplastic Agents, Alkylating Phase 3,Phase 2
17 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
18 Alkylating Agents Phase 3,Phase 2
19 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
21
Isophosphamide mustard Phase 3,Phase 2 0
22 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
23 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Immunological Phase 3,Phase 2,Phase 1
25 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
28 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
29 Anti-Allergic Agents Phase 3
30
Histamine Phosphate Phase 3 51-74-1 65513
31 Neurotransmitter Agents Phase 3
32 Histamine H1 Antagonists Phase 3
33 Serotonin Agents Phase 3
34 Serotonin Antagonists Phase 3
35 Gastrointestinal Agents Phase 3
36 Histamine Antagonists Phase 3
37 Antipruritics Phase 3
38 Dermatologic Agents Phase 3
39
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
40
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
41
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 6857599 5310940 9887054 43805
42
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
43
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
44
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
45
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
46
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
47
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
48
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
49
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
50
Durvalumab Approved, Investigational Phase 2 1428935-60-7

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
2 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
3 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
4 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
5 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
6 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
7 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
8 Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Not yet recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
10 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
11 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
12 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
13 Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
14 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
15 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
16 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
17 Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
18 Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT01168232 Phase 2 Ixabepilone
19 Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
20 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer Completed NCT00075400 Phase 2 imatinib mesylate
21 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer Completed NCT00238121 Phase 2 sorafenib tosylate
22 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer Completed NCT00112489 Phase 2 carboplatin;paclitaxel
23 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
24 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2 ziv-aflibercept
25 Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
26 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
27 Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus Completed NCT00231842 Phase 2 Ifosfamide;Cisplatin
28 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
29 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
30 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
31 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
32 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
33 Chemotherapy in Treating Patients With Sarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
34 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
35 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
36 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
37 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
38 Thalidomide in Treating Patients With Gynecologic Sarcomas Completed NCT00006005 Phase 2 thalidomide
39 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
40 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
41 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) Completed NCT00129727 Phase 2 Paclitaxel;Carboplatin;Bevacizumab
42 Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer Completed NCT00392769 Phase 2 Cetuximab
43 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
44 A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer Recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
45 Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? Recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
46 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer Recruiting NCT03783949 Phase 2 Ganetespib;Niraparib;Carboplatin;Paclitaxel;Gemcitabine
47 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Recruiting NCT02923934 Phase 2 Ipilimumab;Nivolumab
48 Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
49 Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer Recruiting NCT02397083 Phase 2 Everolimus
50 A Study of Nivolumab in Selected Uterine Cancer Patients Recruiting NCT03241745 Phase 2 Nivolumab

Search NIH Clinical Center for Carcinosarcoma

Cochrane evidence based reviews: carcinosarcoma

Genetic Tests for Carcinosarcoma

Anatomical Context for Carcinosarcoma

MalaCards organs/tissues related to Carcinosarcoma:

42
Uterus, Ovary, Breast, Lung, Liver, Cervix, Prostate

Publications for Carcinosarcoma

Articles related to Carcinosarcoma:

(show top 50) (show all 1703)
# Title Authors Year
1
Cutaneous Carcinosarcoma: a Clinicopathologic and Immunohistochemical Analysis of 11 Korean Cases. ( 30618513 )
2019
2
Molecular profiling of the biphasic components of hepatic carcinosarcoma by targeted next-generation sequencing. ( 30629754 )
2019
3
Immunohistochemical analysis of the epithelial to mesenchymal transition in uterine carcinosarcoma. ( 30636710 )
2019
4
Esophageal carcinosarcoma that disappeared pathologically by palliative radiotherapy alone. ( 30649679 )
2019
5
Carcinosarcoma of the esophagus: A report of 6 cases associated with zinc finger E-box-binding homeobox 1 expression. ( 30655804 )
2019
6
The Effect of Fucoidan, a Potential New, Natural, Anti-Neoplastic Agent on Uterine Sarcomas and Carcinosarcoma Cell Lines: ENITEC Collaborative Study. ( 30659312 )
2019
7
Uterine Inversion as a Result of a Large Prolapsed Carcinosarcoma of the Uterus. ( 30686610 )
2019
8
Carcinosarcoma of Vater's papilla: case report of a rare neoplasm and review of the literature. ( 30706323 )
2019
9
Cytological features of uterine carcinosarcoma: A retrospective study of 20 cases with an emphasis on the usefulness of endometrial cytology. ( 30706679 )
2019
10
A rare case of metastatic skin tumors originating from the sarcomatous component of lung carcinosarcoma. ( 30719994 )
2019
11
Multifocal Synchronous Upper Urinary Tract Carcinosarcoma (Sarcomatoid Carcinoma) With Rhabdomyoblastic Differentiation. ( 30767589 )
2019
12
Ovarian carcinosarcoma: Current developments and future perspectives. ( 30771873 )
2019
13
Cutaneous Carcinosarcoma of the Medial Canthus Discovered on Mohs Debulk Analysis. ( 30789518 )
2019
14
The controversy of esophageal carcinosarcoma: A case report and brief review of literature. ( 30855491 )
2019
15
Pulmonary carcinosarcoma characterized by small round cells with neuroendocrine, myogenic, and chondrogenic differentiation: An extremely rare case. ( 30864171 )
2019
16
Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast. ( 30864198 )
2019
17
Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Approved Stage I Uterine Carcinosarcoma: Turkish Gynecologic Oncology Study ( 30873825 )
2019
18
Carcinosarcoma of the Gallbladder with Chondrosarcomatous Differentiation and Intracytoplasmic Eosinophilic Hyaline Globules (Thanatosomes): A Report of a Case and Review of the Literature. ( 30881717 )
2019
19
Primary peritoneal carcinosarcoma: A report of two cases. ( 30910155 )
2019
20
A successfully treated primary peritoneal carcinosarcoma and serous carcinoma of stage IIIC rescued from hypovolemic shock due to tumor rupture. ( 30910157 )
2019
21
Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube. ( 30913944 )
2019
22
Gas Gangrene of Malignant Mixed Mullerian Tumor of Ovary Caused by Clostridium perfringens. ( 29685470 )
2018
23
Lymphadenectomy and Adjuvant Therapy Improve Survival with Uterine Carcinosarcoma: A Large Retrospective Cohort Study. ( 29791913 )
2018
24
Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. ( 29971677 )
2018
25
Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Evaluation of an Interesting Case of Uterine Carcinosarcoma with Isolated Appendicular Skeletal Metastases. ( 29643680 )
2018
26
Trends of uterine carcinosarcoma in the United States. ( 29400015 )
2018
27
Tumor Mutational Burden Guides Therapy in a Treatment Refractory<i>POLE-</i>Mutant Uterine Carcinosarcoma. ( 29386312 )
2018
28
The Association of an Elevated Thrombocyte Count with Clinicopathological Prognostic Factors and Survival in Patients with Uterine Carcinosarcoma. ( 29629727 )
2018
29
Esophageal carcinosarcoma comprised of minimally invasive squamous cell carcinoma and undifferentiated pleomorphic sarcoma: A collision cancer? ( 29934989 )
2018
30
Diagnostic accuracy of 3.0T diffusion-weighted MRI for patients with uterine carcinosarcoma: Assessment of tumor extent and lymphatic metastasis. ( 29437265 )
2018
31
Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. ( 29455465 )
2018
32
Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma. ( 29303931 )
2018
33
Synchronous endometrial adenocarcinoma and carcinosarcoma in endometrial polyp. ( 29854405 )
2018
34
Carcinosarcoma ex Pleomorphic Adenoma of the Submandibular Gland in a 64-Year-Old Man: A Case Report. ( 29540647 )
2018
35
Significance of venous thromboembolism in women with uterine carcinosarcoma. ( 29248197 )
2018
36
Usefulness of ascites cytology for the evaluation of chemotherapy response in ovarian carcinosarcoma. ( 29488261 )
2018
37
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. ( 29426293 )
2018
38
Impact of radiotherapy modalities on outcomes in the adjuvant management of uterine carcinosarcoma: A National Cancer Database analysis. ( 29097136 )
2018
39
Carcinosarcoma of Breast Mimicking Breast Abscess. ( 30288006 )
2018
40
Outcomes of carcinosarcoma in a tertiary care institution in India. ( 29600231 )
2018
41
Morphological features of doxorubicin-resistant Walker 256 carcinosarcoma and response of mast cells. ( 29600974 )
2018
42
Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. ( 29620581 )
2018
43
Primary Cutaneous Carcinosarcoma: A cutaneous neoplasm with an exceptional presentation. ( 29666695 )
2018
44
Locally advanced carcinosarcoma of the pancreas. ( 29706823 )
2018
45
Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report. ( 29719799 )
2018
46
Carcinosarcoma of the esophagus with rapid morphological change. ( 29755123 )
2018
47
Esophageal Carcinosarcoma that Was Diagnosed as a Granulocyte-colony Stimulating Factor and Interleukin-6-producing Tumor with a Tumor Fever. ( 29780130 )
2018
48
A Case of Invasive Sinonasal Carcinosarcoma: The Importance of Early Detection. ( 29850334 )
2018
49
Carcinosarcoma of the parotid gland with abdominal metastasis: a case report and review of literature. ( 29859537 )
2018
50
Trichoblastic Carcinosarcoma of the Skin: A Case Report and Literature Review. ( 29933313 )
2018

Variations for Carcinosarcoma

Cosmic variations for Carcinosarcoma:

9 (show top 50) (show all 124)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1235014 U2AF1 cervix,NS,carcinoma,adenocarcinoma c.467G>A p.R156H 21:43094670-43094670 0
2 COSM10663 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 0
3 COSM10648 TP53 cervix,NS,carcinoma,adenocarcinoma c.524G>A p.R175H 17:7675088-7675088 0
4 COSM44399 TP53 cervix,NS,carcinoma,adenocarcinoma c.677G>T p.G226V 17:7674286-7674286 0
5 COSM11066 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 0
6 COSM10738 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 0
7 COSM11148 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 0
8 COSM10941 TP53 cervix,NS,carcinoma,adenocarcinoma c.730G>A p.G244S 17:7674233-7674233 0
9 COSM10725 TP53 cervix,NS,carcinoma,adenocarcinoma c.701A>G p.Y234C 17:7674262-7674262 0
10 COSM10662 TP53 cervix,NS,carcinoma,adenocarcinoma c.743G>A p.R248Q 17:7674220-7674220 0
11 COSM11333 TP53 cervix,NS,carcinoma,adenocarcinoma c.499C>T p.Q167* 17:7675113-7675113 0
12 COSM11582 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 0
13 COSM10656 TP53 cervix,NS,carcinoma,adenocarcinoma c.742C>T p.R248W 17:7674221-7674221 0
14 COSM6904336 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 0
15 COSM29468 STK11 cervix,NS,carcinoma,adenocarcinoma c.910C>T p.R304W 19:1221996-1221996 0
16 COSM29467 STK11 cervix,NS,carcinoma,adenocarcinoma c.894C>A p.F298L 19:1221980-1221980 0
17 COSM14135 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 0
18 COSM6904335 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 0
19 COSM6967953 SF3B1 cervix,NS,carcinoma,adenocarcinoma c.1910C>G p.S637C 2:197402723-197402723 0
20 COSM6967952 SF3B1 cervix,NS,carcinoma,adenocarcinoma c.2323C>G p.R775G 2:197401789-197401789 0
21 COSM6923797 RET cervix,NS,carcinoma,adenocarcinoma c.1132G>A p.D378N 10:43109099-43109099 0
22 COSM6904334 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 0
23 COSM5802682 PTPRD cervix,NS,carcinoma,adenocarcinoma c.3530G>A p.R1177H 9:8465650-8465650 0
24 COSM5154 PTEN cervix,NS,carcinoma,adenocarcinoma c.697C>T p.R233* 10:87957915-87957915 0
25 COSM5219 PTEN cervix,NS,carcinoma,adenocarcinoma c.388C>G p.R130G 10:87933147-87933147 0
26 COSM5056 PTEN cervix,NS,carcinoma,adenocarcinoma c.1093G>A p.V365I 10:87965353-87965353 0
27 COSM5152 PTEN cervix,NS,carcinoma,adenocarcinoma c.388C>T p.R130* 10:87933147-87933147 0
28 COSM88109 PTEN cervix,NS,carcinoma,adenocarcinoma c.724G>T p.E242* 10:87957942-87957942 0
29 COSM6904339 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 0
30 COSM27133 PIK3CA cervix,NS,carcinoma,adenocarcinoma c.1633G>C p.E545Q 3:179218303-179218303 0
31 COSM6147 PIK3CA cervix,NS,carcinoma,adenocarcinoma c.1636C>G p.Q546E 3:179218306-179218306 0
32 COSM760 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1624G>A p.E542K 3:179218294-179218294 0
33 COSM770 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 0
34 COSM763 PIK3CA cervix,NS,carcinoma,adenocarcinoma c.1633G>A p.E545K 3:179218303-179218303 0
35 COSM21446 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 0
36 COSM29313 PIK3CA cervix,NS,carcinoma,adenocarcinoma c.3129G>A p.M1043I 3:179234286-179234286 0
37 COSM746 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.263G>A p.R88Q 3:179199088-179199088 0
38 COSM24712 PIK3CA cervix,NS,carcinoma,adenocarcinoma c.1638G>T p.Q546H 3:179218308-179218308 0
39 COSM775 PIK3CA cervix,NS,carcinoma,adenocarcinoma c.3140A>G p.H1047R 3:179234297-179234297 0
40 COSM759 PIK3CA cervix,NS,carcinoma,adenocarcinoma c.1616C>G p.P539R 3:179218286-179218286 0
41 COSM94978 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 0
42 COSM12584 PIK3CA cervix,NS,carcinoma,adenocarcinoma c.1357G>A p.E453K 3:179210291-179210291 0
43 COSM766 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 3:179218306-179218306 0
44 COSM564 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 0
45 COSM584 NRAS cervix,NS,carcinoma,adenocarcinoma c.182A>G p.Q61R 1:114713908-114713908 0
46 COSM580 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 0
47 COSM522 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>C p.G12A 12:25245350-25245350 0
48 COSM517 KRAS cervix,NS,carcinoma,adenocarcinoma c.34G>A p.G12S 12:25245351-25245351 0
49 COSM516 KRAS cervix,NS,carcinoma,adenocarcinoma c.34G>T p.G12C 12:25245351-25245351 0
50 COSM521 KRAS cervix,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 12:25245350-25245350 0

Expression for Carcinosarcoma

Search GEO for disease gene expression data for Carcinosarcoma.

Pathways for Carcinosarcoma

Pathways related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CTNNB1 ERBB2 HRAS KIT KRAS MME
2
Show member pathways
13.84 CTNNB1 DES ERBB2 HRAS KIT KRAS
3
Show member pathways
13.5 CTNNB1 ERBB2 HRAS KIT KRAS KRT7
4
Show member pathways
13.45 ERBB2 HRAS KIT KRAS PIK3CA PTEN
5
Show member pathways
13.36 ERBB2 HRAS KIT KRAS MUC1 PIK3CA
6
Show member pathways
13.3 CTNNB1 ERBB2 HRAS KIT KRAS PTEN
7
Show member pathways
13.28 CTNNB1 ERBB2 HRAS KIT KRAS VIM
8
Show member pathways
12.97 CTNNB1 HRAS KRAS PIK3CA PTEN TP53
9
Show member pathways
12.96 CTNNB1 HRAS KRAS PIK3CA PTEN TP53
10
Show member pathways
12.91 ERBB2 HRAS KRAS PIK3CA PTEN
11
Show member pathways
12.91 CTNNB1 ERBB2 HRAS KRAS PIK3CA PTEN
12
Show member pathways
12.91 CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
13
Show member pathways
12.88 ERBB2 HRAS KRAS PIK3CA PTEN
14 12.78 ERBB2 HRAS KIT KRAS TP53
15
Show member pathways
12.75 CTNNB1 HRAS KIT KRAS PIK3CA
16
Show member pathways
12.72 CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
17
Show member pathways
12.71 ERBB2 HRAS KRAS PIK3CA PTEN TP53
18
Show member pathways
12.69 CTNNB1 HRAS KRAS PIK3CA PTEN
19
Show member pathways
12.69 ERBB2 HRAS KIT KRAS PIK3CA PTEN
20
Show member pathways
12.67 CTNNB1 ERBB2 HRAS KRAS PIK3CA PTEN
21 12.65 CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
22
Show member pathways
12.63 CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
23
Show member pathways
12.61 ERBB2 HRAS KRAS PIK3CA TP53
24
Show member pathways
12.59 HRAS KRAS PIK3CA PTEN
25 12.55 ACTC1 DES KRT7 MUC1 VIM
26
Show member pathways
12.54 ERBB2 HRAS KRAS PIK3CA PTEN TP53
27
Show member pathways
12.51 ERBB2 HRAS KRAS PIK3CA PTEN
28
Show member pathways
12.48 CTNNB1 ERBB2 HRAS KIT KRAS PGR
29
Show member pathways
12.47 CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
30
Show member pathways
12.45 HRAS KRAS PIK3CA VIM
31
Show member pathways
12.44 CTNNB1 DES HRAS KRAS
32
Show member pathways
12.43 HRAS KIT KRAS PIK3CA
33
Show member pathways
12.42 CTNNB1 HRAS KRAS PIK3CA
34
Show member pathways
12.42 CTNNB1 ERBB2 HRAS KIT KRAS PIK3CA
35
Show member pathways
12.41 HRAS PIK3CA PTEN TP53
36
Show member pathways
12.4 HRAS KRAS PIK3CA PTEN
37 12.39 CTNNB1 HRAS KRAS PIK3CA TP53
38
Show member pathways
12.35 HRAS KRAS PIK3CA PTEN
39
Show member pathways
12.32 ERBB2 HRAS KRAS PIK3CA
40 12.32 HRAS KRAS PIK3CA TP53
41 12.28 ERBB2 HRAS KRAS PIK3CA PTEN TP53
42
Show member pathways
12.24 ERBB2 HRAS KRAS PIK3CA PTEN TP53
43 12.24 CTNNB1 ERBB2 HRAS KRAS PIK3CA TP53
44 12.22 HRAS KRAS PIK3CA PTEN TP53
45 12.21 ERBB2 HRAS KRAS PTEN
46
Show member pathways
12.2 HRAS KIT PIK3CA PTEN
47
Show member pathways
12.2 HRAS KRAS PIK3CA TP53
48
Show member pathways
12.19 ERBB2 HRAS KRAS PIK3CA PTEN
49 12.18 CTNNB1 KRAS PTEN TP53
50
Show member pathways
12.17 HRAS KRAS PIK3CA TP53

GO Terms for Carcinosarcoma

Cellular components related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.73 ACTC1 CTNNB1 DES ERBB2 HRAS KRAS
2 focal adhesion GO:0005925 9.55 ACTC1 CTNNB1 KRAS MME VIM
3 cytoplasm GO:0005737 9.5 ACTC1 CTNNB1 DES ERBB2 HRAS KIT
4 fascia adherens GO:0005916 9.32 CTNNB1 DES
5 plasma membrane GO:0005886 10 CTNNB1 DES ERBB2 HRAS KIT KRAS

Biological processes related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 CTNNB1 HRAS KIT KRAS PTEN
2 cell proliferation GO:0008283 9.8 CTNNB1 ERBB2 HRAS PTEN TP53
3 phosphatidylinositol phosphorylation GO:0046854 9.76 ERBB2 KIT PIK3CA
4 MAPK cascade GO:0000165 9.76 ERBB2 HRAS KIT KRAS
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.75 CTNNB1 KIT PTEN
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.69 HRAS KIT PTEN
7 Ras protein signal transduction GO:0007265 9.67 HRAS KRAS TP53
8 positive regulation of MAPK cascade GO:0043410 9.62 CTNNB1 ERBB2 HRAS KIT
9 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.61 HRAS KRAS MUC1
10 epithelial tube branching involved in lung morphogenesis GO:0060441 9.59 CTNNB1 KRAS
11 regulation of synaptic transmission, GABAergic GO:0032228 9.57 KRAS PTEN
12 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.56 MUC1 TP53
13 negative regulation of apoptotic process GO:0043066 9.56 ACTC1 CTNNB1 PTEN TP53
14 positive regulation of phospholipase C activity GO:0010863 9.55 HRAS KIT
15 replicative senescence GO:0090399 9.54 MME TP53
16 muscle filament sliding GO:0030049 9.54 ACTC1 DES VIM
17 response to isolation stress GO:0035900 9.48 HRAS KRAS
18 positive regulation of MAP kinase activity GO:0043406 9.46 ERBB2 HRAS KIT KRAS
19 cytokine-mediated signaling pathway GO:0019221 9.43 KIT KRAS MUC1 PIK3CA TP53 VIM
20 positive regulation of gene expression GO:0010628 9.28 ACTC1 CTNNB1 ERBB2 HRAS KIT KRAS

Molecular functions related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 DES ERBB2 PGR PTEN TP53 VIM
2 protein phosphatase binding GO:0019903 9.43 CTNNB1 ERBB2 TP53
3 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.13 ERBB2 KIT PIK3CA
4 protein C-terminus binding GO:0008022 8.92 CTNNB1 ERBB2 HRAS VIM
5 protein binding GO:0005515 10 CTNNB1 DES ERBB2 HRAS KIT KRAS

Sources for Carcinosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....